Lanean...
Burosumab: A new drug to treat hypophosphatemic rickets
Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets. A report enclosed in this letter gives a brief review of current knowledge on buro...
Gorde:
| Argitaratua izan da: | Sudan J Paediatr |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Discover Publishing Group
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845463/ https://ncbi.nlm.nih.gov/pubmed/29545670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.24911/SJP.2017.2.11 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|